Gerresheimer Q2 2026 Adjusted EBITDA Soars Over 50% QoQ

• Q2 2026 revenue was EUR 578 million, up EUR 55 million quarter on quarter but below the EUR 614 million reported in Q2 2025.
• Adjusted EBITDA rose by more than 50% quarter on quarter to EUR 102 million; the Q2 adjusted EBITDA margin improved 5 percentage points to 17.6%.
• First-half 2026 revenue totaled EUR 1.10 billion and adjusted EBITDA was EUR 168 million, both down year on year; the half-year EBITDA margin was approximately 15.3%.
• Containment & Delivery Systems performed strongly, with first-half revenue of EUR 604 million and adjusted EBITDA of EUR 135 million, supported by higher demand for drug-delivery devices.
• Primary Injectable Solutions weakened amid lower demand for syringe systems and injection vials: first-half revenue fell to EUR 212 million and adjusted EBITDA to EUR 16 million.
• Gerresheimer expects a stronger second half; the Centor sale is nearing completion, while the Primary Packaging Plastics sale is expected to close in H1 2027.

The next important date, The half-year results are scheduled to be published in September/October., at Gerresheimer is on 30.09.2026.

The price of Gerresheimer at the time of the news was 28,76EUR and was up +4,35 % compared with the previous day.
15 minutes after the article was published, the price was 29,32EUR this corresponds to a plus of +1,95 % since publication.

Gerresheimer

+4,17 %

+5,49 %

+8,07 %

+3,09 %

+9,26 %

-70,86 %

-62,55 %

-57,55 %

-31,86 %

ISIN:DE000A0LD6E6WKN:A0LD6E

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max

Gerresheimer direkt bei SMARTBROKER+ handelnKaufVerkauf

Aktion Dein iPhone, dein Gewinn! Mitmachen und mit etwas Glück eines von 5 iPhone Duo gewinnen! Bei SMARTBROKER+ stehen dir dafür 3 Wege offen. Jetzt Depot eröffnen und sichern!

Schreibe Deinen Kommentar